Stenzl, A., Shore, N. D., Villers, A., Iguchi, T., Gomez-Veiga, F., Alcaraz, A., … Armstrong, A. J. (2022). Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES. In EUROPEAN UROLOGY (Vol. 81, pp. S776–S777).

Stenzl, A., N. D. Shore, A. Villers, T. Iguchi, F. Gomez-Veiga, A. Alcaraz, B. Alekseev, et al. “Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES.” In EUROPEAN UROLOGY, 81:S776–77, 2022.

Stenzl A, Shore ND, Villers A, Iguchi T, Gomez-Veiga F, Alcaraz A, et al. Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES. In: EUROPEAN UROLOGY. 2022. p. S776–7.

Stenzl, A., et al. “Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES.” EUROPEAN UROLOGY, vol. 81, 2022, pp. S776–77.

Stenzl A, Shore ND, Villers A, Iguchi T, Gomez-Veiga F, Alcaraz A, Alekseev B, Azad AA, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Rosbrook B, Zohren F, Haas GP, Gourgioti G, El-Chaar NN, Armstrong AJ. Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES. EUROPEAN UROLOGY. 2022. p. S776–S777.